Literature DB >> 18337481

Uric acid and incident kidney disease in the community.

Daniel E Weiner1, Hocine Tighiouart, Essam F Elsayed, John L Griffith, Deeb N Salem, Andrew S Levey.   

Abstract

Uric acid may mediate aspects of the relationship between hypertension and kidney disease via renal vasoconstriction and systemic hypertension. To investigate the relationship between uric acid and subsequent reduced kidney function, limited-access data of 13,338 participants with intact kidney function in two community-based cohorts, the Atherosclerosis Risks in Communities and the Cardiovascular Health Study, were pooled. Mean baseline serum uric acid was 5.9 +/- 1.5 mg/dl, mean baseline serum creatinine was 0.9 +/- 0.2 mg/dl, and mean baseline estimated GFR was 90.4 +/- 19.4 ml/min/1.73 m(2). During 8.5 +/- 0.9 yr of follow-up, 712 (5.6%) had incident kidney disease defined by GFR decrease (>or=15 ml/min/1.73 m(2) with final GFR <60 ml/min/1.73 m(2)), while 302 (2.3%) individuals had incident kidney disease defined by creatinine increase (>or=0.4 mg/dl with final serum creatinine >1.4 mg/dl in men and 1.2 mg/dl in women). In GFR- and creatinine-based logistic regression models, baseline uric acid level was associated with increased risk for incident kidney disease (odds ratio 1.07 [95% confidence interval 1.01 to 1.14] and 1.11 [95% confidence interval 1.02 to 1.21] per 1-mg/dl increase in uric acid, respectively), after adjustment for age, gender, race, diabetes, systolic BP, hypertension, cardiovascular disease, left ventricular hypertrophy, smoking, alcohol use, education, lipids, albumin, hematocrit, baseline kidney function and cohort; therefore, elevated serum uric acid level is a modest, independent risk factor for incident kidney disease in the general population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337481      PMCID: PMC2396939          DOI: 10.1681/ASN.2007101075

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

1.  Area socioeconomic status and progressive CKD: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Sharon Stein Merkin; Josef Coresh; Ana V Diez Roux; Herman A Taylor; Neil R Powe
Journal:  Am J Kidney Dis       Date:  2005-08       Impact factor: 8.860

2.  Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension.

Authors:  Daniel I Feig; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Richard J Johnson
Journal:  Hypertension       Date:  2006-05-08       Impact factor: 10.190

3.  Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease.

Authors:  Daniel E Weiner; Sayed Tabatabai; Hocine Tighiouart; Essam Elsayed; Nisha Bansal; John Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2006-09       Impact factor: 8.860

4.  Hyperuricemia and incidence of hypertension among men without metabolic syndrome.

Authors:  Eswar Krishnan; C Kent Kwoh; H Ralph Schumacher; Lewis Kuller
Journal:  Hypertension       Date:  2006-12-26       Impact factor: 10.190

5.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults.

Authors:  Manjula Kurella; Joan C Lo; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2005-05-18       Impact factor: 10.121

6.  Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study.

Authors:  Michelle C Odden; Glenn M Chertow; Linda F Fried; Anne B Newman; Stephanie Connelly; Sara Angleman; Tamara B Harris; Eleanor M Simonsick; Michael G Shlipak
Journal:  Am J Epidemiol       Date:  2006-10-11       Impact factor: 4.897

7.  Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.

Authors:  Michael G Shlipak; Ronit Katz; Mark J Sarnak; Linda F Fried; Anne B Newman; Catherine Stehman-Breen; Stephen L Seliger; Brian Kestenbaum; Bruce Psaty; Russell P Tracy; David S Siscovick
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

Review 8.  Uric acid, the metabolic syndrome, and renal disease.

Authors:  Pietro Cirillo; Waichi Sato; Sirirat Reungjui; Marcelo Heinig; Michael Gersch; Yuri Sautin; Takahiko Nakagawa; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

9.  Plasma uric acid level and risk for incident hypertension among men.

Authors:  John P Forman; Hyon Choi; Gary C Curhan
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

10.  Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.

Authors:  Areef Ishani; Greg A Grandits; Richard H Grimm; Kenneth H Svendsen; Allan J Collins; Ronald J Prineas; James D Neaton
Journal:  J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 10.121

View more
  164 in total

1.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.

Authors:  Richard J Johnson; Miguel A Lanaspa; Eric A Gaucher
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

2.  Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families.

Authors:  Andrew D Rule; Mariza de Andrade; Martha Matsumoto; Tom H Mosley; Sharon Kardia; Stephen T Turner
Journal:  Rheumatology (Oxford)       Date:  2010-12-24       Impact factor: 7.580

Review 3.  Uric acid as a mediator of diabetic nephropathy.

Authors:  Diana I Jalal; David M Maahs; Peter Hovind; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

4.  Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents.

Authors:  Stephanie Nguyen; Hyon K Choi; Robert H Lustig; Chi-yuan Hsu
Journal:  J Pediatr       Date:  2009-04-17       Impact factor: 4.406

Review 5.  SLC2A9--a fructose transporter identified as a novel uric acid transporter.

Authors:  Myphuong T Le; Mohamed Shafiu; Wei Mu; Richard J Johnson
Journal:  Nephrol Dial Transplant       Date:  2008-07-07       Impact factor: 5.992

6.  Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function.

Authors:  Kim Hughes; Tanya Flynn; Janak de Zoysa; Nicola Dalbeth; Tony R Merriman
Journal:  Kidney Int       Date:  2013-09-18       Impact factor: 10.612

Review 7.  Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.

Authors:  Samir G Mallat; Sahar Al Kattar; Bassem Y Tanios; Abdo Jurjus
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

8.  Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.

Authors:  Fatemeh Ghane Sharbaf; Farahnak Assadi
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

9.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

Review 10.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.